Consint.AIThe Story
Consint.AI, a Noida-based deeptech company working on healthcare and insurance risk management, has raised ₹22 crore (approximately $2.3 million) in a Series A funding round. The round was backed by BIG Global Investment JSC, Equanimity Ventures Trust II and Seafund Venture India Scheme I. No single investor was named as the lead. Consint.AI has not disclosed the valuation at which the round was raised, the equity diluted, the split of the ₹22 crore across the three backers, or whether the capital arrives in one tranche. Equanimity and Seafund are returning investors, having led the company's ₹5 crore seed round in January 2025, so the Series A is an extension of an existing relationship rather than a new set of backers. The company has stated that the proceeds will fund global expansion, strengthen its AI research and enterprise delivery, and support the development of a foundational model for detecting fraud, waste and abuse across healthcare, insurance, banking and financial services. It plans to expand across India, the Middle East, Africa, the United States and Southeast Asia. Founded in 2020 by Ashish Chaturvedi, and later joined by co-founder Swadeep Singh, Consint.AI builds software for claims processing, document forensics and clinical intelligence. The company says it has assessed more than 100 million transactions and identified over ₹1,000 crore in fraud using more than 500 machine-learning models, fine-tuned large language models and over 500 digitised clinical protocols. These figures are company-reported and have not been independently verified.
Why It Matters
Consint.AI sells AI software to the organisations that pay healthcare and insurance claims. Its systems screen claims for fraud, waste and abuse, process documents, and run what the company calls clinical intelligence, targeting the gap between what is billed and what should have been paid. The customer is the insurer, the hospital network or the government health scheme, not the patient, which ties the company's revenue to enterprise procurement rather than consumer adoption. The problem it addresses is real and expensive. Claims leakage through fraudulent, duplicated or inflated billing is a persistent cost for payers, and the manual review that catches it does not scale to the transaction volumes modern insurers handle. Software that flags suspect claims automatically has a clear economic case: the payer keeps a share of what it would otherwise have paid out. The mechanism by which Consint.AI makes money is less clearly established. The source does not disclose revenue, customer count or contract structure, and the company has not published audited financials. Its earlier funding was small, a ₹5 crore seed in January 2025, which suggests the business is at an early commercial stage where the technology is further along than the revenue. What can be said is that the reported traction is described in activity, not income. Assessing 100 million transactions and identifying ₹1,000 crore in fraud measures what the models have processed, not what customers have paid to use them. Those are engineering milestones. Whether they convert into recurring enterprise contracts is the open question the Series A is meant to answer.
The Strategic Read
The market assumption changing behind this investment is that fraud, waste and abuse in health and insurance claims is large enough, and structured enough, to be attacked by a dedicated AI layer rather than absorbed as a cost of doing business. Insurers have historically treated leakage as unavoidable; Consint.AI is betting that a purpose-built model recovers enough to justify paying for it. Where value is captured depends on whether the product sits inside the payer's workflow or beside it. Fraud detection that flags claims after payment saves less than one that blocks them before disbursement, and enterprise sales into insurers and government health programmes are slow, reference-driven and procurement-heavy. The ₹22 crore has to cover both deepening those integrations and the stated push into the Middle East, Africa, the US and Southeast Asia at once, which is a wide brief for a round this size. The claim worth scrutinising is the foundational model. Building a base model for fraud across healthcare, insurance and banking is a materially harder and more capital-intensive undertaking than fine-tuning existing LLMs on claims data, which is what the company appears to do today. A ₹22 crore Series A does not fund frontier model training; the more likely reading is a domain-adapted model built on open weights, and the language of a "foundational model" should be read against that budget. The durability question is data access. If Consint.AI's edge is the volume of claims it has processed and the clinical protocols it has digitised, that compounds only while it retains privileged access to payer data. Incumbents like Innovaccer, and the payers' own in-house teams, sit on far larger datasets. The largest execution risk is that fraud detection becomes a feature inside a broader claims platform rather than a standalone product a payer will buy on its own.
For daily, sharp analysis of the biggest moves in the Indian business and startup ecosystem, follow StartupFox.
